Huge from WH on PBM middlemen: The Order builds

Huge from WH on PBM middlemen:

The Order builds off that critical work and reevaluates the role of middlemen by:
Improving disclosure of fees that pharmaceutical benefit managers (PBMs) pay to brokers for steering employers to utilize their services.
Directing the administration to develop reforms to promote a more competitive, transparent, efficient, and resilient prescription drug value chain.

By addressing the influence of middlemen and promoting open competition, President Trump’s actions aim to create a fairer prescription drug market that lowers costs and ensures accountability across the health care system.

https://www.whitehouse.gov/fact-sheets/2025/0...ug-prices/

There it is -- a huge issue being addressed & from what posts/articles I've read over last years, the PBM's are a huge piece of the puzzle of drugs prescribed for favor, etc.. --- Mark Cuban even talks about these middle men & his drug company price transparency. He says pricing transparency is #1 issue

Have posted several times with all of the ancillary benefits Leronlimab brings to the table --- Cytodyn advantages are so abundant, no need to "price gouge", ever. Again, we can not be priced out of a disease by a "competitor".

The world is going to love Cytodyn upon realizing LL & LL-PLS pricing to benefits, & Vs others.

No other non-toxic, non death inducing drug for any disease indication like our Leronlimab.

Ladies of Leronlimab MOA is the starting point.

May.